After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia

Delia, Mario; Carluccio, Paola; Mestice, Anna; Frappampina, R.; Albano, Francesco; Specchia, Giorgina; Musto, Pellegrino

doi:10.1155/2020/2134647

Cited by 3 publications

(2 citation statements)

References 39 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amount of regulatory T cells (Treg) has decreased in BM of AML patients who responded to chemotherapy, but failed to decrease in non-responding patients [ 217 ]. Also combined treatment with chemotherapy and histone deacetylase (HDAC) inhibitor panobinostat led to decreased number of TNFR2+ Treg in blood and BM of AML patients [ 218 ].…”

Section: Immune Response Recovery After Therapy In Myeloid Leukemimentioning

confidence: 99%

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Swatler

Turos-Korgul

Kozłowska

et al. 2021

Cancers

View full text Add to dashboard Cite

Both chronic myeloid leukemia and acute myeloid leukemia evade the immune response during their development and disease progression. As myeloid leukemia cells modify their bone marrow microenvironment, they lead to dysfunction of cytotoxic cells, such as CD8+ T cells or NK cells, simultaneously promoting development of immunosuppressive regulatory T cells and suppressive myeloid cells. This facilitates disease progression, spreading of leukemic blasts outside the bone marrow niche and therapy resistance. The following review focuses on main immunosuppressive features of myeloid leukemias. Firstly, factors derived directly from leukemic cells – inhibitory receptors, soluble factors and extracellular vesicles, are described. Further, we outline function, properties and origin of main immunosuppressive cells - regulatory T cells, myeloid derived suppressor cells and macrophages. Finally, we analyze interplay between recovery of effector immunity and therapeutic modalities, such as tyrosine kinase inhibitors and chemotherapy.

show abstract

Section: Immune Response Recovery After Therapy In Myeloid Leukemimentioning

confidence: 99%

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Swatler

Turos-Korgul

Kozłowska

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…As a type of immunosuppressive cells, high expression of Tregs cells has been shown to result in the escape of tumor cells [ 29 , 30 ]. Studies have reported that the expression of Tregs cells is higher in acute myeloid leukemia (AML) patients compared to healthy individuals [ 31 ], and that Tregs contribute to immune escape through the suppression of anti-leukemia treatment [ 32 ]. Macrophages, as a component of immune cells, play a crucial role in the inflammatory and tumor microenvironment [ 33 ], and are often implicated in the establishment of a microenvironment that is favorable to tumor progression through various mechanisms [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Exploration of cuprotosis-related genes for predicting prognosis and immunological characteristics in acute myeloid leukaemia based on genome and transcriptome

Wei

Miao

Guo

et al. 2023

Aging

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is a common hematologic malignancy with a generally unfavorable prognosis. Cuprotosis as a new form of programmed cell death has been shown to play an important role in tumorigenesis and progression; However, the relationship between cuprotosis and the prognosis of AML patients remains unclear. Methods: Transcriptomic and genomics data, along with clinical information, were obtained from the TCGA and GEO databases. Especially, unsupervised clustering and machining learning were used to identify molecular subtypes and cuprotosis-related risk scores respectively. Kaplan-Meier analysis, univariate and multivariate Cox regression, and Receiver Operator Characteristic curve (ROC) were performed to assess the prognosis based on cuprotosis-related genes (CRGs). Moreover, multiple algorithms were used to evaluate immunological heterogeneity among patients with different risk scores. For in vitro analysis, the expression of genes involved in CRGs was detected by Quantitative Reverse Transcription Polymerase (qRT-PCR) in AML patients. Results: Transcriptomic and genome data indicated the immense heterogeneity in the CRGs landscape of normal and tumor samples. Cuprotosis subtype A and cuprotosis regulatory subtype B in the genomics map and biological characteristics were significantly different from the other groups. Furthermore, these two subtypes had lower risk scores and longer survival times compared to other groups. Cox analyses indicated that risk score was an independent prognostic factor for AML patients. In addition, our risk score could be an indicator of survival outcomes in immunotherapy datasets. Conclusions: Our study demonstrates the potential of CRGs in guiding the prognosis, treatment, and immunological characteristics of AML patients.

show abstract

Immune‐dysregulation harnessing in myeloid neoplasms

Sharifi,

Xu,

Nasiri

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

Myeloid malignancies arise in bone marrow microenvironments and shape these microenvironments in favor of malignant development. Immune suppression is one of the most important stages in myeloid leukemia progression. Leukemic clone expansion and immune dysregulation occur simultaneously in bone marrow microenvironments. Complex interactions emerge between normal immune system elements and leukemic clones in the bone marrow. In recent years, researchers have identified several of these pathological interactions. For instance, recent works shows that the secretion of inflammatory cytokines such as tumor necrosis factor‐α (TNF‐α), from bone marrow stromal cells contributes to immune dysregulation and the selective proliferation of JAK2V617F+ clones in myeloproliferative neoplasms. Moreover, inflammasome activation and sterile inflammation result in inflamed microenvironments and the development of myelodysplastic syndromes. Additional immune dysregulations, such as exhaustion of T and NK cells, an increase in regulatory T cells, and impairments in antigen presentation are common findings in myeloid malignancies. In this review, we discuss the role of altered bone marrow microenvironments in the induction of immune dysregulations that accompany myeloid malignancies. We also consider both current and novel therapeutic strategies to restore normal immune system function in the context of myeloid malignancies.

show abstract

After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia

Cited by 3 publications

References 39 publications

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Exploration of cuprotosis-related genes for predicting prognosis and immunological characteristics in acute myeloid leukaemia based on genome and transcriptome

Immune‐dysregulation harnessing in myeloid neoplasms

Contact Info

Product

Resources

About